Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma arising from the cervical epithelium. It accounts for approximately 15% of invasive cervical carcinomas. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors. Grossly, advanced cervical adenocarcinoma may present as an exophytic mass, an ulcerated lesion, or diffuse cervical enlargement. Microscopically, the majority of cervical adenocarcinomas are of the endocervical (mucinous) type. 
Cervical adenocarcinomas most frequently harbor alterations in TP53, KRAS, PIK3CA, PTEN, and SMAD4 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KRAS Mutation, and PIK3CA Mutation are the most common alterations in cervical adenocarcinoma .
There are 23 clinical trials for cervical adenocarcinoma, of which 22 are open and 1 is completed or closed. Of the trials that contain cervical adenocarcinoma as an inclusion criterion, 2 are phase 1 (1 open), 6 are phase 1/phase 2 (6 open), 9 are phase 2 (9 open), and 6 are phase 3 (6 open).
PD-L1 is the most frequent gene inclusion criterion for cervical adenocarcinoma clinical trials .
Pembrolizumab, placebo, and bevacizumab are the most common interventions in cervical adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.